Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16981168 | CELLULAR SIGNALING DOMAIN ENGINEERING IN CHIMERIC ANTIGEN RECEPTOR-MODIFIED REGULATORY T CELLS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | Final Rejection | AMGEN INC. |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | Non-Final OA | ImmunityBio, Inc. |
| 17810287 | ADA-RESPONSE SPECIFICATION ASSAY | Final Rejection | Hoffmann-La Roche Inc. |
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | Non-Final OA | Synthekine, Inc. |
| 18169293 | AMHR2-ED CANCER VACCINE FORMULATIONS | Non-Final OA | The Cleveland Clinic Foundation |
| 17047993 | COMPOSITIONS AND METHODS FOR TREATING MELANOMA WITH A CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17915870 | Antigen Binding Proteins to Class 5 ETEC Adhesins | Non-Final OA | United States of America as Represented by the Secretary of the Navy |
| 17819745 | PD-L1 ANTIBODIES BINDING CANINE PD-L1 | Non-Final OA | Intervet Inc. |
| 18390978 | TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS | Non-Final OA | Caribou Biosciences, Inc. |
| 17818256 | FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT | Final Rejection | FIVE PRIME THERAPEUTICS, INC. |
| 18263753 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR ROR1 AND CD3 | Non-Final OA | Numab Therapeutics AG |
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 18329960 | EXOSOME COMPRISING OVEREXPRESSED FC RECEPTOR OR PORTION THEREOF, AND METHOD FOR PREPARING SAME | Non-Final OA | EXOCOBIO INC |
| 18164952 | Covalent Diabodies and Uses Thereof | Non-Final OA | MacroGenics, Inc. |
| 18023060 | MODIFIED IMMUNE CELLS FOR FIBROSIS AND INFLAMMATION | Non-Final OA | Resolution Therapeutics Limited |
| 18079858 | COMPOSITION FOR OVERCOMING RESISTANCE TO EGFR-TARGETING AGENT | Non-Final OA | Pinetree Therapeutics, Inc. |
| 17641520 | RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS | Final Rejection | CSL BEHRING LENGNAU AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy